[Application of neoadjuvant immunotherapy in head and neck squamous cell carcinoma: From mechanisms to clinical practice]

【新辅助免疫疗法在头颈部鳞状细胞癌中的应用:从机制到临床实践】

阅读:1

Abstract

Most patients with head and neck squamous cell carcinoma (HNSCC) present with locally advanced disease at the time of diagnosis. Current standard treatment strategies mainly include surgery-based multimodal therapy or concurrent chemoradiotherapy. However, existing treatment approaches remain insufficient to meet the therapeutic needs of patients with locally advanced HNSCC. Surgical resection often requires extensive removal of tissues, resulting in functional impairment and substantial deterioration in quality of life. Although concurrent chemoradiotherapy is widely used, patients still face a high risk of early recurrence. The addition of induction chemotherapy may reduce organ dysfunction, but it has not demonstrated a clear improvement in long-term survival and is associated with considerable treatment-related toxicity. In recent years, immunotherapy has shown promising efficacy across multiple malignancies and has reshaped treatment paradigms in certain tumor types. Nevertheless, its application in HNSCC has largely been limited to patients with recurrent or metastatic disease. Based on the theoretical rationale for combining immunotherapy with radiotherapy and chemotherapy, increasing attention has been directed toward advancing the timing of immunotherapy to the neoadjuvant setting. Early integration of immunotherapy may help overcome immunosuppressive barriers, modulate the tumor immune microenvironment, induce durable antitumor immunity, and remodel the immune landscape, thereby promoting tumor regression. This approach has the potential to achieve tumor downstaging, increase resectability, preserve organ function, and improve patients' quality of life. This review summarizes and analyzes the biological mechanisms, current clinical evidence, and existing limitations of neoadjuvant immunotherapy in patients with HNSCC, with the aim of providing safer and more effective treatment options for locally advanced disease. Future perspectives on the development and optimization of neoadjuvant immunotherapy strategies in HNSCC are also discussed.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。